Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 27, 2019

View Archived Issues

Less can be more for HIV vaccines, in several ways

Lipids and lupus

FDA approves advancement of Plenitude study with PPP-001

La Jolla re-evaluates its development of LJPC-401 due to mixed clinical results

Activated NK-92 cell regimens show activity in Merkel cell carcinoma trial

There's an app for that?!: web-based tool facilitates new antibiotic development

DNDi receives financial support development of drugs for sleeping sickness and river blindness

FDA approves Exservan oral film for the treatment of ALS

Successful completion of Stage 2 of phase II study of prexigebersen plus decitabine in AML

Targeting miR-26a shows therapeutic potential in model of abdominal aortic aneurysm

NOTCH3 expression as a predictor of poor survival in patients with ESCC

Preliminary phase I/II data presented for olutasidenib in advanced IDH1-mutant gliomas

Dizal Pharmaceutical describes new HER2 inhibitors

New monocarboxylate transporter 4 inhibitors identified at AstraZeneca

Janssen Pharmaceutica presents dual SGLT1 and SGLT2 inhibitors

Muscarinic acetylcholine M3 receptor positive allosteric modulators patented by Nippon Shinyaku

Bayer identifies new quinoline derivatives

RPL13 variants cause a ribosomopathy defined by a rare skeletal dysplasia with severe short stature

Intronic TTTTA/TTTCA expansions in MARCH6 lead to familial adult myoclonic epilepsy

Loss-of-function allele in SLC30A8 improves insulin secretion and protects from type 2 diabetes

Benefit seen with pyrotinib plus SHR-6390 in patients with HER2-positive resistant gastric cancer

Prescient reports third complete response in phase Ib study of PTX-200 for AML